Hypereosinophilic Syndrome
📧 Sign up to get email alerts when something new happens for Hypereosinophilic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment [Phase 3]
Phase 3 rollover trial to continue benralizumab (Fasenra) in participants who completed a prior study and benefited from treatment; not yet …
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome [Phase 2]
Phase 2 clinical trial update shows a tyrosine kinase inhibition approach for eosinophilic myeloid neoplasms, including hypereosinophilic sy…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Identification of New Markers in the Hypereosinophilic Syndrome [NA]
This completed clinical trial explored identification of new biomarkers for hypereosinophilic syndrome. The study was conducted at Universit…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) [Phase 3]
The SPHERE Phase 3 pediatric trial investigating treatment for hypereosinophilic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
This ClinicalTrials.gov update reports the completion of the TrinetX study on Hypereosinophilic Syndrome without an identifiable non-haemato…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: Steroid Treatment for Hypereosinophilic Syndrome [Phase 4]
Phase 4 trial update on steroid treatment for hypereosinophilic syndrome completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome [Phase 2, Phase 3]
A clinical trial update evaluating the safety and efficacy of benralizumab for hypereosinophilic syndrome across Phase 2 and Phase 3 stages.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [NA]
Clinical trial update of imatinib mesylate for various myeloproliferative and related neoplasms including CMML, CML, polycythemia vera, hype…
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/2 study of oral AMN107 (imatinib) in adults with chronic myeloid leukemia and other hematologic malignancies has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 [Phase 3]
Extension safety study update for mepolizumab in hypereosinophilic syndrome (Phase 3; completed; results posted).
-
CLINICAL_TRIALS trial_result · 2020-05-05Clinical Trial Update: Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) [Phase 3]
Phase 3 trial update for intravenous mepolizumab in subjects with hypereosinophilic syndromes (HES) has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-21Clinical Trial Update: Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) [Phase 3]
Phase 3 trial evaluating efficacy and safety of mepolizumab in subjects with severe hypereosinophilic syndrome has completed with posted res…
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) [Phase 2]
Phase 2 trial evaluating dasatinib for myeloproliferative disorders; the study has completed and results were posted in 2019.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes [Phase 2]
Phase 2 clinical trial evaluating imatinib mesylate in patients with various activated tyrosine kinase-driven malignancies, including hypere…
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome [Phase 3]
Phase 3 open-label extension trial of intravenous mepolizumab for hypereosinophilic syndrome was terminated, with results posted in December…
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) [Phase 2]
Phase 2 trial evaluating cladribine (2-Chlorodeoxyadenosine) in combination with cytarabine for idiopathic hypereosinophilic syndrome has co…
-
CLINICAL_TRIALS trial_result · 2012-05-01Clinical Trial Update: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome [Phase 2]
A Phase 2 study evaluating the safety and efficacy of Imatinib Mesylate in patients with Idiopathic Hypereosinophilic Syndrome has been term…
-
CLINICAL_TRIALS trial_result · 2012-03-13Clinical Trial Update: Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. [Phase 1]
A pediatric pharmacokinetic study of Glivec/Gleevec (imatinib) in children aged 1 to less than 4 with chronic myeloid leukemia, Philadelphia…
-
CLINICAL_TRIALS trial_result · 2010-12-29Clinical Trial Update: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes [Phase 2]
A Phase 2 clinical trial evaluated the efficacy of imatinib mesylate in hypereosinophilic syndromes and has completed, reporting efficacy si…
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome [Phase 2]
A Phase 2 trial of an anti-Interleukin-5 antibody for hypereosinophilic syndrome has completed.